ARAF as a New Driver in Lung Adenocarcinoma
Luiz H. Araujo, MD, medical oncologist, Corporate Cancer Foundation fellow, Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, discusses the discovery of oncogenic ARAF as a new driver for lung cancer.
Luiz H. Araujo, MD, medical oncologist, Corporate Cancer Foundation fellow, Ohio State’s Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute, discusses the discovery of oncogenicARAFas a new driver for lung cancer.
Clinical Pearls:
- When a 66-year-old lung cancer patient responded to sorafenib, her tumor and normal tissue was taken for sequencing.
- Researchers found a new mutation called ARAF.
- When ARAF is placed in cell lines, the cell lines develop tumors.
- It was found that sorafenib can reverse the phenotype.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
